To the Editor:Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally.Hepatocellular carcinoma(HCC)accounts for 90%of primary liver cancers with the highest inc...To the Editor:Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally.Hepatocellular carcinoma(HCC)accounts for 90%of primary liver cancers with the highest incidence in China(more than 50%of all cases worldwide)[1].Liver transplantation(LT)is regarded as an optimal therapy for selected HCC patients.The Milan criteria are the benchmark for candidate selection that ensure excellent prognosis for patients with HCC[2].The Hangzhou criteria expand 51.5%more of Milan criteria for LT candidates with comparable posttransplant survivals[3].However,LT recipients fulfilling Milan criteria or Hangzhou criteria are at the risk of up to 13%−18%HCC recurrence rate within five years[4].Only 25%−50%of recurrent HCC patients post-LT are eligible for surgical treatment which have consistently presented favored survival benefit than systemic therapy[5].展开更多
As a relatively uncommon orphan tumor with high mortality,biliary tract cancer(BTC)presents an aggressive course and heterogeneous clinical features[1].BTC patients present with advanced manifestations[2].Unfortunatel...As a relatively uncommon orphan tumor with high mortality,biliary tract cancer(BTC)presents an aggressive course and heterogeneous clinical features[1].BTC patients present with advanced manifestations[2].Unfortunately,there has been little progress in the management of BTC.Most patients have inoperable lesions and must receive palliative therapy.Gemcitabine-based chemotherapy has been the only widely accepted first-line treatment for advanced BTC[3].Nevertheless,BTCs are often refractory to chemotherapeutic regimens,leading to a poor clinical outcome in these patients.Recently,with the rapid development of next generation sequencing(NGS)technologies,some actionable mutations such as those in IDH1,FGFR2,BRAF,HER2 genes,and unique molecular subsets in BTCs have been identified[4],and related targeted therapy against actionable mutations has been introduced into clinical practice as a promising therapeutic strategy[5].展开更多
基金supported by grants from the National Science and Technology Major Project(2017ZX10203201)Health Com-mission of Zhejiang Province(2016KYA073 and 2019KY540)
文摘To the Editor:Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally.Hepatocellular carcinoma(HCC)accounts for 90%of primary liver cancers with the highest incidence in China(more than 50%of all cases worldwide)[1].Liver transplantation(LT)is regarded as an optimal therapy for selected HCC patients.The Milan criteria are the benchmark for candidate selection that ensure excellent prognosis for patients with HCC[2].The Hangzhou criteria expand 51.5%more of Milan criteria for LT candidates with comparable posttransplant survivals[3].However,LT recipients fulfilling Milan criteria or Hangzhou criteria are at the risk of up to 13%−18%HCC recurrence rate within five years[4].Only 25%−50%of recurrent HCC patients post-LT are eligible for surgical treatment which have consistently presented favored survival benefit than systemic therapy[5].
基金supported by a grant from Department of Education of Zhejiang Province(Y201636437)
文摘As a relatively uncommon orphan tumor with high mortality,biliary tract cancer(BTC)presents an aggressive course and heterogeneous clinical features[1].BTC patients present with advanced manifestations[2].Unfortunately,there has been little progress in the management of BTC.Most patients have inoperable lesions and must receive palliative therapy.Gemcitabine-based chemotherapy has been the only widely accepted first-line treatment for advanced BTC[3].Nevertheless,BTCs are often refractory to chemotherapeutic regimens,leading to a poor clinical outcome in these patients.Recently,with the rapid development of next generation sequencing(NGS)technologies,some actionable mutations such as those in IDH1,FGFR2,BRAF,HER2 genes,and unique molecular subsets in BTCs have been identified[4],and related targeted therapy against actionable mutations has been introduced into clinical practice as a promising therapeutic strategy[5].
